Rheumatoid arthritis Archives

Gilead invests $5.1bn in Belgian biotech Galapagos

https://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/

GSK takes aim at RA market, pitting otilimab against Pfizer and Sanofi rivals in phase 3

https://pharmaphorum.com/news/gsk-takes-aim-at-ra-market-pitting-otilimab-against-pfizer-and-sanofi-rivals-in-phase-3/

AbbVie makes case for Humira follow-on upadacitinib at EULAR

https://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/

Patients switch to lower dose of Pfizer’s RA pill after safety signal

https://pharmaphorum.com/news/patients-switch-to-lower-dose-of-pfizers-ra-pill-after-safety-signal/

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

https://pharmaphorum.com/news/abbvies-jak-inhibitor-upadacitinib-gets-priority-review/

Navigating new frontiers: Ways to find space in the future RA market

https://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/

Galapagos shares surge on RA drug trial results

https://pharmaphorum.com/news/galapagos-shares-surge-drug-trial-results/

Biosimilars underused in rheumatoid arthritis on the NHS – experts

https://pharmaphorum.com/news/biosimilars-underused-rheumatoid-arthritis-nhs-experts/

Celltrion hopes to outdo inflammatory disease rivals with SC infliximab

https://pharmaphorum.com/news/celltrion-hopes-to-outdo-inflammatory-disease-rivals-with-sc-infliximab/

Search